

Gynecology Oncology (GynOnc) Disease-Oriented Team

Clinical Research Treatment Trial Flowchart

OVARIAN/ENDOMETRIAL

UCI 24-146

REGN5668 + REGN4018 or Cemiplimab
 Coord: Jiana Ejbara
 Accrual: 0/5

MUTATIONS

UCI 22-78

KSQ-4279 +/- Olaparib or Carboplatin
 Targeting deleterious mutation (germline
 or somatic)
 Coord: Jiana Ejbara
 Accrual: 1/5

UCI 23-186

Long-term safety and efficacy of
 Pembrolizumab
 Coord: Jiana Ejbara
 Accrual: 1/8

PLATINUM-RESISTANT RECURRENCE

>3L

GOG-3076

Platinum Doublet + Bevacizumab +/-OlviVec
 Coord: Jiana Ejbara
 Accrual: 2/5

PLATINUM-SENSITIVE RECURRENCE

FRa + and >1L

GOG-3078

Mirvetuximab Soravtansine
 Coord: Jiana Ejbara
 Accrual: 0/5

OVARIAN CANCER

UCI 21-190

Assessing the Predictive Capability of Circulating
Tumor DNA as a Screening Tool for Ovarian
Cancer

ctDNA

Coord: Jiana Ejbara

Accrual: 2/36

UCI 22-40

VIRGO2

Coord: Jiana Ejbara

Accrual: